Topical advances in PIM kinases and their inhibitors: Medicinal chemistry perspectives.
ATP competitive
Apoptosis
Mutation
PIM kinase
Prostate cancer
Serine-threonine kinase
Journal
Biochimica et biophysica acta. Reviews on cancer
ISSN: 1879-2561
Titre abrégé: Biochim Biophys Acta Rev Cancer
Pays: Netherlands
ID NLM: 9806362
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
05
01
2022
revised:
21
03
2022
accepted:
25
03
2022
pubmed:
4
4
2022
medline:
9
6
2022
entrez:
3
4
2022
Statut:
ppublish
Résumé
Cytosolic PIM kinases are the members of serine/ threonine family play a crucial role in the cancer progression and development. Overexpression of PIM kinases is observed in various types of cancers including prostate, hematological, pancreatic, breast carcinoma and likewise. PIM kinases have now been considered as limelight target for the discovery of new molecules as novel anticancer agents as no drug is in the market targeting PIM kinases. In the last two decades, numerous PIM kinase inhibitors have been developed and few of them were in clinical trial phases but could not pass the pipeline of the clinical trials. The present comprehensive review intends to cover biological and the structural aspects of PIM kinases and also medicinal chemistry of PIM inhibitors developed in recent years.
Identifiants
pubmed: 35367531
pii: S0304-419X(22)00050-6
doi: 10.1016/j.bbcan.2022.188725
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
Proto-Oncogene Proteins c-pim-1
EC 2.7.11.1
proto-oncogene proteins pim
EC 2.7.11.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
188725Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.